Deciphera Pharmaceuticals, Inc. (DCPH)
After hours:
| Previous Close | 17.98 |
| Open | 17.78 |
| Bid | 17.10 x 1000 |
| Ask | 17.33 x 800 |
| Day's Range | 17.23 - 18.08 |
| 52 Week Range | 6.51 - 22.76 |
| Volume | |
| Avg. Volume | 706,601 |
| Market Cap | 1.291B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.90 |
| Earnings Date | Feb 06, 2023 - Feb 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.78 |
- Business Wire
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., January 24, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,986,111 shares of its common stock. The shares of common stock sold include 1,041,666 shares pursuant to the option granted by Deciphera to the underwriters, which option was exercised in full. The
- Business Wire
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
WALTHAM, Mass., January 24, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of additional data from the planned exploratory analysis from the INTRIGUE Phase 3 clinical study of QINLOCK® using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatin
- Business Wire
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass., January 20, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00 per share. The aggregate gross proceeds to Deciphera from this offering are expected to be approximately $125 million, before
